Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.36 |
| ▸ | RORC | P51449 | 8/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | STK17B | O94768 | 1/20 | 0.32 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6497617 | 0.78 | MAPKAPK2 (0.41) | MAPKAPK2RORCATRS1PR3CA12 | |
| SCHEMBL25399078 | 0.78 | RORC (0.40) | MAPKAPK2RORCSCN9AS1PR3 | |
| SCHEMBL31423753 | 0.77 | MAPKAPK2 (0.41) | MAPKAPK2RORCATRS1PR3STK17B | |
| SCHEMBL21608474 | 0.74 | MALT1 (0.44) | MAPKAPK2RORCATRS1PR3 | |
| SCHEMBL26640996 | 0.74 | MAPKAPK2 (0.45) | MAPKAPK2RORCATRCYP17A1 | |
| SCHEMBL1010435 | 0.72 | ATR (0.46) | MAPKAPK2RORCATRSTK17BSTK17A | |
| SCHEMBL23580479 | 0.71 | MALT1 (0.42) | — | |
| SCHEMBL6491966 | 0.70 | MAPKAPK2 (0.47) | MAPKAPK2RORCATRS1PR3STK17B | |
| SCHEMBL18805715 | 0.69 | RORC (0.53) | MAPKAPK2RORCATRSCN9ASTK17B | |
| SCHEMBL18839612 | 0.69 | MAPKAPK2 (0.41) | MAPKAPK2RORCATRSTK17BSTK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197384-A1 | AZOLE COMPOUND AND ANTIFUNGAL AGENT | NIHON NOHYAKU CO., LTD. (JP) | 2025-06-19 | — | — | US | disclosed |
| EP-4495114-A1 | AZOLE COMPOUND AND ANTIFUNGAL AGENT | Nihon Nohyaku Co., Ltd. (JP) | 2025-01-22 | — | — | EP | disclosed |
| WO-2023176957-A1 | AZOLE COMPOUND AND ANTIFUNGAL AGENT | 日本農薬株式会社 | 2023-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197384-A1 | AZOLE COMPOUND AND ANTIFUNGAL AGENT | CBR3, ERG28, CBR1 | MAPKAPK2 3462/4885RORC 459/4885ATR 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.